niuz

Chinese drug iza-bren doubles lung cancer survival window in phase 3 trial

1 source
One source
What the source said
South China Morning Post – China
“Chinese drug iza-bren doubles lung cancer survival window in phase 3 trial”

An anticancer drug developed by Sichuan Biokin Pharmaceutical took centre stage in a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Congress in Madrid last week. Researchers said the drug, iza-bren, showed a significant advantage over platinum-based chemotherapy in a phase 3 randomised, double-blind clinical trial conducted at 73 hospitals in China and involving 432 patients with advanced lung cancer. The median progression-free survival (PFS) – the length…

Read at South China Morning Post – China
Is this point wrong? Tell us

Reported by one source so far. It is confirmed when a second, independent source reports the same thing.

Top world stories now

How recent

The shading behind a date drains as it ages: full when new, three quarters at 1 hour, half at 6 hours, a quarter at 12 hours, empty after a day. The date is when the source published it.

Timeline

The line under a story shows when it was reported. Now is at the end. The shaded part runs from its first article to its latest; each mark is an article, taller where several came out within 15 minutes. In lists the line is the last two days, so stories compare; a faded start means the story began earlier. On a story page it runs from the first article to now.